Helei Hou

1.7k total citations
72 papers, 1.2k citations indexed

About

Helei Hou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Helei Hou has authored 72 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Helei Hou's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (9 papers) and Gastric Cancer Management and Outcomes (9 papers). Helei Hou is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (9 papers) and Gastric Cancer Management and Outcomes (9 papers). Helei Hou collaborates with scholars based in China, United States and Sweden. Helei Hou's co-authors include Xiaochun Zhang, Dantong Sun, Man Jiang, Chao Ge, Liang Yu, Jinjun Li, Hong Li, Na Zhou, Kang Qin and Chuantao Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Helei Hou

64 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Helei Hou China 21 494 467 428 288 167 72 1.2k
Ning Lv China 22 373 0.8× 482 1.0× 290 0.7× 304 1.1× 162 1.0× 71 1.3k
Oscar Alabiso Italy 24 651 1.3× 427 0.9× 450 1.1× 280 1.0× 165 1.0× 60 1.5k
Francisco Javier Ramos Spain 15 625 1.3× 771 1.7× 422 1.0× 192 0.7× 172 1.0× 42 1.4k
Chung-Tsen Hsueh United States 19 556 1.1× 416 0.9× 305 0.7× 200 0.7× 93 0.6× 55 1.2k
Yongchun Song China 21 352 0.7× 477 1.0× 360 0.8× 351 1.2× 94 0.6× 75 1.2k
Manuel Valladares‐Ayerbes Spain 20 685 1.4× 672 1.4× 359 0.8× 469 1.6× 192 1.1× 74 1.4k
Zhonghua Wang China 20 683 1.4× 415 0.9× 409 1.0× 265 0.9× 114 0.7× 57 1.3k
Dale R. Shepard United States 17 478 1.0× 419 0.9× 470 1.1× 258 0.9× 95 0.6× 75 1.2k
Leni van Doorn Netherlands 18 537 1.1× 540 1.2× 430 1.0× 126 0.4× 111 0.7× 56 1.2k
A. Benjamin Suttle United States 21 744 1.5× 636 1.4× 706 1.6× 257 0.9× 160 1.0× 36 1.5k

Countries citing papers authored by Helei Hou

Since Specialization
Citations

This map shows the geographic impact of Helei Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helei Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helei Hou more than expected).

Fields of papers citing papers by Helei Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helei Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helei Hou. The network helps show where Helei Hou may publish in the future.

Co-authorship network of co-authors of Helei Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Helei Hou. A scholar is included among the top collaborators of Helei Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helei Hou. Helei Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Hou, Helei, Nan Li, Chao Liu, et al.. (2025). Enhanced nitrogen removal in a micro-polluted drinking water reservoir by a new WLA-Bio® system: Mechanisms and applications. Water Research. 290. 125119–125119.
4.
Zhao, Heping, Helei Hou, Jingliang Chen, et al.. (2024). Profiles of Lymphocyte Subtypes in HIV‐Infected People With Different Immunologic Responses to Antiretroviral Therapy. Journal of Medical Virology. 96(11). e70081–e70081. 1 indexed citations
5.
Zhou, Hai, et al.. (2023). Role of YES1 signaling in tumor therapy resistance. SHILAP Revista de lepidopterología. 2(3). 210–218. 5 indexed citations
6.
Sun, Dantong, Han Zhao, Hai Zhou, et al.. (2023). ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma. Translational Oncology. 33. 101685–101685. 3 indexed citations
7.
Zhang, Xuchen, Chuantao Zhang, Helei Hou, et al.. (2023). Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study. Translational Oncology. 31. 101657–101657. 13 indexed citations
8.
Zhou, Haiyu, Dantong Sun, Chunxiao Miao, et al.. (2023). The stage-dependent prognostic role of ARID1A in hepatocellular carcinoma. Translational Cancer Research. 12(11). 3088–3104. 5 indexed citations
9.
Sun, Dantong, Li Wang, Jialin Qu, et al.. (2023). Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer. Journal of Translational Medicine. 21(1). 150–150. 19 indexed citations
10.
Sun, Dantong, Wei‐Hua Yan, Jingjuan Zhu, et al.. (2022). Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. Technology in Cancer Research & Treatment. 21. 2213870302–2213870302. 5 indexed citations
11.
Hou, Helei, Yongjie Wang, Dantong Sun, et al.. (2022). Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China. Investigational New Drugs. 41(1). 86–92. 8 indexed citations
12.
Sun, Dantong, Yan Zhu, Han Zhao, et al.. (2021). Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis. Cellular Oncology. 44(5). 1019–1034. 33 indexed citations
13.
Wang, Li, Jialin Qu, Na Zhou, et al.. (2020). Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomedicine & Pharmacotherapy. 130. 110626–110626. 24 indexed citations
14.
Sun, Dantong, Wei‐Hua Yan, Hua Zhu, Qiaoling Liu, & Helei Hou. (2020). Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing. Frontiers in Oncology. 10. 574523–574523. 5 indexed citations
15.
Jiang, Man, Chuantao Zhang, Dong Liu, et al.. (2019). Influence and mechanism of lung cavitation development on antiangiogenic therapy. Translational Lung Cancer Research. 8(4). 500–512. 11 indexed citations
16.
Sun, Dantong, Helei Hou, Chuantao Zhang, & Xiaochun Zhang. (2018). The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis. OncoTargets and Therapy. Volume 11. 6539–6554. 18 indexed citations
17.
Hou, Helei, Xiaonan Yang, Jinping Zhang, et al.. (2017). Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Scientific Reports. 7(1). 14605–14605. 21 indexed citations
18.
Zhang, Xue, et al.. (2017). Concordance study between IBM Watson for Oncology (WFO) and clinical practice for breast and lung cancer patients in China. Annals of Oncology. 28. x170–x170. 6 indexed citations
19.
Ma, Chong, et al.. (2016). Prognostic significance of immune cells in the tumor microenvironment and peripheral blood of gallbladder carcinoma patients. Clinical & Translational Oncology. 19(4). 477–488. 16 indexed citations
20.
Zhang, Lixing, Hefen Sun, Fangyu Zhao, et al.. (2012). BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma. Cancer Research. 72(16). 4276–4285. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ning Lv Breakdown of academic impact, for papers by Oscar Alabiso Breakdown of academic impact, for papers by Francisco Javier Ramos Breakdown of academic impact, for papers by Chung-Tsen Hsueh Breakdown of academic impact, for papers by Yongchun Song Breakdown of academic impact, for papers by Manuel Valladares‐Ayerbes Breakdown of academic impact, for papers by Zhonghua Wang Breakdown of academic impact, for papers by Dale R. Shepard Breakdown of academic impact, for papers by Leni van Doorn Breakdown of academic impact, for papers by A. Benjamin Suttle
Rankless by CCL
2026